The 2025 Nobel Prize in Physiology or Medicine honors Dr. Fred Ramsdell, Dr. Mary E. Brunkow, and Dr. Shimon Sakaguchi for discoveries that transformed our understanding of the immune system. In exclusive interviews, Ventures Accelerated speaks with Nobel laureate Fred Ramsdell, Dr. Karin Rosén of Diamyd Medical, Sarah Fredriksson of Aqilion, and Dr. Patricia Beckmann to explore how decades of research are now translating into new treatments for autoimmune and inflammatory diseases.

What can this year’s Nobel Prize in Economics teach biotech? In this editorial, Anders Månson dives into the laureates’ ideas on innovation-driven growth and creative destruction to unpack today’s biotech “funding winter.” He challenges the industry’s growing risk aversion and explores how rekindling bold innovation could reignite the sector’s momentum.

Meet our Accelerator, Ingela Hallberg, MD, with 25+ years across AstraZeneca, Bayer, and IQVIA. She discusses the biggest challenges for Nordic companies, from early clinical planning to reimbursement strategies.

Discover her vision for how the Nordics can stay at the forefront of global innovation.

In our conversation with Johan Bloom, CEO of Curus and experienced healthtech investor, we unpack the psychology of investor indecision, from fear of missing out to complex decision chains. He shares actionable insights on how founders can manage expectations, maintain momentum, and build trust throughout the fundraising journey.

In today’s tough funding climate, many biotech founders find themselves waiting endlessly for investor replies that never come. But knowing when to move on and how to keep momentum can make all the difference.

We introduce Jonas Ekstrand—a scientist, entrepreneur, and ecosystem builder with more than three decades of experience in life science. From pioneering cancer research to leading SwedenBIO and co-founding Nordic Life Science Days, he has dedicated his career to advancing collaboration and strengthening the Nordic region’s global presence. He shares his reflections on building a multifaceted career, the mentors who inspired him, and the untapped potential of the Nordic life science ecosystem.

Cell & Gene Therapy Insights recently published an article by Helena Strigård, Founder of Ventures Accelerated, exploring the untapped medical and market potential in women’s health and the transformative role of AI and precision medicine. 

In conversations with Roger Lias and Maria Lundius, we found that the Nordics are a strategic entry point into Europe for life sciences, combining faster clinical trials, high-quality data, strong biomanufacturing capacity, and a uniquely collaborative culture that accelerates development and de-risks scale-up.

FDA’s recent move to waive requirements for clinical efficacy studies (CESs) to approve of monoclonal antibody biosimilars certainly redefines the regulatory landscape for biologic drugs. This decision opens the door to new strategies and players in the biosimilars sector. The impact of FDA’s new approval policy is thus potentially very significant, promising lower development costs, faster patient access, and certainly enhanced competition, particularly benefiting generic and biotech firms. 

Learn how SANC is transforming neurosurgery across Africa through visionary collaboration — and support the mission at the Impact Days gala on December 11 in Stockholm, featuring global leaders turning bold ideas into lasting impact.

Facing $300 billion in lost revenue from expiring patents, Big Pharma is turning to M&A to secure future growth — triggering a wave of dealmaking across the Biotech sector. Major players are snapping up companies in high-value areas like oncology, neuroscience, and AI-enabled platforms. While this creates valuable exit opportunities for mature Biotechs, early-stage innovators may struggle as buyers focus on de-risked assets. To stand out in this climate, Biotech firms need sharp, targeted partnering strategies.